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Purpose: The canonical wingless and Int1 (Wnt) signaling pathway plays key roles in multiple biologic events. The
pathway co-receptor, low density lipoprotein receptor-related protein 5 (LRP5), is involved in the pathogenesis of retinal
diseases and has been implicated in glaucoma. We studied whether a disease-associated polymorphism LRP5.Q89R,
which is located in the second blade of the first β-propeller domain, directly alters Wnt signaling activity with cell-based
assays.
Methods: The LRP5.Q89R polymorphism was evaluated by transfection of HEK293T or GTM3 cells with expression
vectors. LRP5 expression and interaction with the molecular chaperone mesoderm development (MESD) were determined
by western immunoblotting and co-immunoprecipitation analyses. To compare membrane-associated LRP5 proteins,
surface proteins were labeled with biotin and pulled down with avidin beads followed by western immunoblotting. TCF-
reporter plasmid-based luciferase assays were used to determine whether LRP5.Q89R affects the canonical Wnt signaling,
or has altered efficacy to suppression by Dickkopf-1 (DKK-1).
Results: Cell-based assays showed that this polymorphism did not change protein expression, interaction with the
molecular chaperone MESD, protein trafficking, Wnt signaling transduction, or its efficacy in DKK1-mediated inhibition.
Conclusions: Our data suggest that this specific polymorphism does not appear to alter the canonical Wnt signaling
pathway. Further studies of LRP5 polymorphisms are needed to elucidate their roles in various associated diseases.
Low  density  lipoprotein  receptor-related  protein  5
(LRP5)  (GenBank:  NM_002335)  is  a  co-receptor  of  the
canonical wingless and Int1 (Wnt) signaling pathway [1]. The
canonical  Wnt-β-catenin  signaling  pathway  regulates
multiple biologic events including proliferation, apoptosis,
and development [2,3]. In the absence of the Wnt protein or
other  pathway  activators,  a  protein  destruction  complex
consisting  of  adenomatous  polyposis  coli  (APC),  Axin,
glycogen  synthase  kinase  3  (GSK3),  and  casein  kinase  1
(CK1) forms in the cytoplasm. This complex phosphorylates
the transcription factor β-catenin, marking it for ubiquination
and degradation by the proteosome. When a Wnt ligand binds
to its receptor Frizzled (FZD) and co-receptor LRP5 or LRP6,
a signal is transduced through Dishevelled (DVL), leading to
disassembly  of  the  protein  destruction  complex.
Unphosphorylated β-catenin accumulates in the cytoplasm
and  subsequently  translocates  into  the  nucleus,  where  it
regulates gene expression by interaction with T cell factor/
lymphoid enhancer factor (TCF/LEF) transcription factors.
Dysregulation of this signaling pathway has been reported in
cancers, bone, and ocular diseases [4].
As a co-receptor of the canonical Wnt signaling pathway,
LRP5  plays  an  important  role  in  signal  transduction  and
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regulation. Its intracellular domain may be phosphorylated by
CK1 and serve as a docking site for Axin, facilitating the
disassembly of the Axin-APC-GSK3-CK1 protein complex
[5].  The  LRP5  extracellular  domain,  however,  provides
binding sites for some of the secreted Wnt pathway inhibitors.
For  example,  secreted  Wnt  pathway  inhibitor  Dickkopf-1
(DKK-1) blocks the Wnt pathway by binding to LRP5 and
disrupting the formation of Wnt-FZD-LRP5 complex [6,7].
Studies have shown that LRP5 plays key roles in eye
development and eye diseases [8]. LRP5 knockout or mutant
mice have persistent hyaloid vessels or incomplete peripheral
retina vascularization [9,10]. These phenotypes are similar to
human familial exudative vitreoretinopathy (FEVR). Genetic
screening of human patients has discovered diverse LRP5
polymorphisms that are associated with these diseases [11,
12]. Complete LRP5 polymorphism information is available
at The National Center for Biotechnology Information, which
contains  more  than  40  reported  disease-associated  LRP5
SNPs.  Another  helpful  source  of  LRP5  polymorphism  is
available at Atlas of Genetics and Cytogenetics in Oncology
and Haematology. LRP5 polymorphisms causing missense
mutations which are either eye disease-related or have been
biologically studied are listed in Table 1.
In addition to the diseases described above, the canonical
Wnt  signaling  pathway  has  recently  been  implicated  in
primary  open  angle  glaucoma  (POAG)  [13].  POAG  is  a
leading cause of visual impairment and blindness worldwide
[14]. This disease is characterized by optic neuropathy and
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894progressive, painless loss of peripheral vision. Although the
exact mechanisms of POAG are not clear, clinical studies have
shown that elevated intraocular pressure (IOP) is an important
risk factor for developing POAG, and lowering IOP slows
disease  progression  and  protects  retinal  ganglion  cells
[15-18]. Our previous studies showed that expression of the
Wnt antagonist secreted frizzled-related protein 1 (SFRP1) is
elevated in the trabecular meshwork cells of POAG patients
[13]. Increased expression of SFRP1 significantly elevated
IOP in perfusion cultured human eyes and in mouse eyes.
Topical ocular administration of a selective GSK3β inhibitor,
which  stabilizes  β-catenin  and  enhances  Wnt  signaling
activity,  blocked  SFRP1-induced  IOP  elevation  in  mouse
eyes.
All these findings suggest that the canonical Wnt pathway
plays important roles in the pathogenesis of retinal diseases
as  well  as  glaucoma.  We  wanted  to  determine  whether
disease-associated  Wnt  gene  family  polymorphisms/
mutations  directly  alter  Wnt  signaling  activity.  We  first
examined LRP5 due to its importance in canonical Wnt signal
transduction.  One  polymorphism,  LRP5.Q89R  has  been
associated with eye diseases [19,20]. LRP5 protein structure
is shown in Figure 1. It has an intracellular domain, a single
transmembrane  domain  and  an  extracellular  domain
containing a signal peptide, four EGF-like domains, which are
separated by four β-propeller domains and three low density
lipoprotein receptor (LDLR) repeats [21]. Each β-propeller
domain has six blades and five tyrosine-tryptophan-threonine-
aspartic acid (YWTD) motifs [22]. The Q89R polymorphism
is located in the second blade of the first β-propeller domain.
Although LRP5.Q89R is disease-associated, whether and
how LRP5.Q89R affects the Wnt pathway remains unclear.
We studied this polymorphism in terms of its expression,
interaction  with  a  molecular  chaperone,  trafficking  and
TABLE 1. SUMMARY OF DISEASE-ASSOCIATED LRP5 POLYMORPHISMS.
cDNA change* Protein
change
Associated diseases/
phenotype
Effect on Wnt
signaling
Biochemical phenotype References
c266A>G Q89R FEVR; LBM; spinal
osteoarthritis
Unknown Unknown [20,32]
c331G>T D111Y HBM Increase Decreases Dkk1 and SOST
inhibition
[26,30]
c461G>T R154M HBM Increase Decreases SOST inhibition [26]
c511G>C G171R HBM Increase Decreases Dkk1 and SOST
inhibition
[30]
c512G>T G171V HBM Increase Decreases MESD binding;
decreased cell surface
presentation; decreased SOST
inhibition/binding
[26,28]
c593A>G N198S HBM Increase Decreases SOST inhibition [26]
c640G>A A214T HBM Increase Decreases Dkk1 and SOST
inhibition/binding
[26,30]
c724G>A A242T HBM Increase Decreases Dkk1 and SOST
inhibition/binding
[30]
c758C>T T253I HBM Increase Decreases Dkk1 and SOST
inhibition/binding
[26,30]
c844A>G M282V HBM Increase Decreases Dkk1 and SOST
inhibition/binding
[30]
c1330C>T R444C FEVR Decrease Inhibits Norrin-FZD4 mediated
pathway activation
[20]
c1481G>A R494Q OPPG Decrease Increases Dkk1 inhibition [8,22]
c1564G>A A522T FEVR Decrease Inhibits norrin-FZD4 mediated
pathway activation
[20]
c1708C>T R570W OPPG Decrease Increases Dkk1 inhibition [8,22]
c3989C>T A1330V FEVR Decrease Inhibits norrin-FZD4 mediated
pathway activation
[20]
c4574T>C# V1525A# BMD# Decrease Unknown [34]
c4619C>T T1540M FEVR Decrease Inhibits norrin-FZD4 mediated
pathway activation
[20]
c4643G>T C1548F FEVR Decrease Inhibits norrin-FZD4 mediated
pathway activation
[20]
        *The number starts from the first nucleotide of the coding region. #The predominant allele is controversial [34]. The SNP
        database recorded c4574C (1525A) as the predominant type. However, c4574C (1525A) is less capable of signal transduction
        compared  to c4574T (1525V). HBM: high bone mineral density; LBM: low bone mineral density; OPPG: Osteoporosis-
        pseudoglioma syndrome.
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895functionality in HEK293T cells because this cell line has been
well  characterized  and  widely  used  in  studying  the  Wnt
signaling  pathway.  Because  cell  signaling  pathways  and
associated functions are often cell-type specific, we also tested
LRP5.Q89R in a trabecular meshwork cell line GTM3. Our
data suggest that this specific polymorphism does not alter the
canonical Wnt signaling pathway.
Figure  1.  The  structure  of  LRP5.  The  LRP5  protein  has  an
intracellular  domain  (white  rectangle),  a  single  transmembrane
domain (black rectangle), an extracellular domain containing a signal
peptide  (blue  rectangle),  four  EGF-like  domains  (green  circles)
which are separated by four β-propeller domains (black vertical line
and horizontal red bars), and three LDLR repeats (white ovals). Each
β-propeller domain has six blades (short black bars) and five YWTD
motifs (red bars). The Q89R polymorphism is located in the second
blade of the first β-propeller domain (arrow).
METHODS
Vector construction: The human DKK1 expression vector,
pcDNA3.1-DKK1 was constructed by subcloning the human
DKK1  coding  sequence  (CDs)  into  pcDNA3.1MycHisC
(Invitrogen, Carlsbad, CA) at 5′ KpnI and 3′ NotI restriction
sites,  respectively.  The  Kozak  sequence  was  introduced
upstream  of  the  start  codon  of  DKK1  CDs  to  enhance
expression [23]. The stop codon was kept so that only the
native DKK1, not a fusion protein with the MycHis tag, is
expressed. pcDNA3.1-hLRP5.WT-MycHisC and pcDNA3-
mMESD-FLAG were kind gifts from Drs. Matthew Warman
(HHMI/Childrens  Hospital/Harvard,  Boston,  MA)  and
Bernadette Holdener (Stony Brook University, Stony Brook,
NY),  respectively.  pcDNA3.1-hLRP5.Q89R-MycHisC  and
pcDNA3.1-hLRP5.G171V-MycHisC  were  constructed  by
mutating the pcDNA3.1-hLRP5.WT-MycHisC vector using
a Site Directed Mutagenesis Kit (Agilent Technologies, Santa
Clara, CA). The empty control vector, pcDNA3.1MycHisC
was  constructed  by  digesting  pcDNA3.1-LRP5.WT-
MycHisC with EcoRI and EcoRV and ligating the remaining
ends  after  blunting  with  Klenow  fragment  (New  England
Biolabs, Ipswich, MA). All vectors were sequence-verified by
Genewiz (Genewiz Inc., South Plainfield, NJ) or the DNA
Core Facility at the University of Iowa, Iowa City, IA.
Protein expression study: HEK293T/17 (ATCC, Manassas,
VA) or GTM3 cells (a gift from Alcon Research, Ltd., Fort
Worth, Texas) [24] were cultured with low glucose-DMEM
(Thermoscientific, Worcester, MA), 10% fetal bovine serum
(Invitrogen)  with  1%  penicilin+streptomycin  and  2  mM
glutamine (Thermoscientific). Four hundred ng empty vector,
pcDNA3.1-LRP5.WT-MycHisC or pcDNA3.1-LRP5.Q89R-
MycHisC was transfected into 4×105 HEK293T/17 cells or
GTM3  cells  in  a  12-well  plate  with  2.4  μl  SureFECT™
transfection reagent (Qiagen, Frederick, MD). Eighteen hours
after  transfection,  medium  was  changed  and  cells  were
cultured for an additional 24 h. Cells were then washed and
scraped in ice-old PBS. Cell pellets were incubated with M-
PER  lysis  buffer  (Thermoscientific)  plus  a  proteinase
inhibitor cocktail (Thermoscientific) on ice. Supernatant was
collected for protein estimation with the Dc Protein Assay Kit
(Bio-Rad, Hercules, CA). For western blotting, 30 μg of total
protein was run on an 8% SDS–PAGE gel and transferred to
a  polyvinylidene  fluoride  (PVDF)  membrane.  The  LRP5
fusion protein was detected with a mouse anti-cMyc antibody
(9E10;  Santa  Cruz  Biotechnology,  Santa  Cruz,  CA).
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was
used as an internal loading control and was probed with rabbit
anti-GAPDH  (Cell  Signaling,  Beverly,  MA).  Secondary
antibodies (goat anti mouse-HRP and anti rabbit-HRP) were
purchased  from  Thermoscientific,  Santa  Cruz,  or  Cell
Signaling.  Antibody  signals  were  detected  using  Femto
substrate (Thermoscientific), and images were captured by the
FluroChem imaging system (Cell Biosciences, Santa Clara,
CA). Experiments were performed in biologic replicates.
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896Densitometry study: To quantitate protein expression levels,
the optic density of LRP5 and GAPDH protein bands were
measured from the digital image by the AlphaEasyFc software
(Cell  Biosciences)  or  ImageJ  (NIH,  Bethesda,  MD).  Two
normalizations were performed for statistical analysis. First,
the  expression  of  LRP5  was  normalized  with  GAPDH.
Second, the expression of LRP5.WT was set at 100% and
LRP5.Q89R was then normalized to LRP5.WT.
Co-immunoprecipitation (Co-IP) and pull-down assay: One
or two μg of empty vector, pcDNA3.1-LRP5.WT-MycHisC,
pcDNA3.1-LRP5.Q89R-MycHisC,  or  pcDNA3.1-
LRP5.G171V-MycHisC was co-transfected with 1 or 0.5 ug
pcDNA3-MESD-FLAG into 3.5×106 HEK293T/17 cells or
2×106 GTM3 cells grown in 60 mm culture dishes using
12 μl SureFECT™ transfection reagent (Qiagen). Eighteen
hours after transfection, medium was changed and cells were
cultured for an additional 24 h. Cells were then washed and
scraped  in  ice-old  PBS.  Cell  pellets  were  incubated  with
binding/wash  buffer  (TBS  with  1%  Triton  X-100)  plus
proteinase inhibitors cocktail (Thermoscientific) on ice. After
brief sonication, 100 μg total protein from each dish was
incubated with 2 μg mouse anti-FLAG antibody (M2; Agilent
Technologies) in a total volume of 200 μl. After 2 h incubation
at 4 °C, the protein and antibody mix was incubated with
10 μl of magnetic Protein G particles (New England Biolabs)
at 4 °C for 1 h. Particles were separated with a magnetic stand
(Promega,  Madison,  WI)  and  washed  with  binding/wash
buffer four times. Particles were boiled in 2× Laemmli buffer
with  β-mercaptoethanol  for  western  immunoblotting.
Experiments were performed in biologic replicates.
Surface protein labeling: Protocols for labeling cell surface
proteins were adapted from previously published methods
[25,26]. In the 60 mm culture dish, 1 or 2 μg empty vector,
pcDNA3.1-LRP5.WT-MycHisC,  pcDNA3.1-LRP5.Q89R-
MycHisC,  or  pcDNA3.1-LRP5.G171V-MycHisC  was
transfected into 3.5×106 HEK293T/17 or 2×106 GTM3 cells
using  6  μl  SureFECT™  transfection  reagent  (Qiagen).
Eighteen hours after transfection, medium was changed and
cells were cultured for 24 h. Cells were washed with ice-old
PBS containing 1 mM MgCl2 and 1 mM CaCl2. After a PBS
wash, 0.5 ml of Sulfo-NHS-LC-Biotin (0.5mg/ml in PBS;
Thermoscientific) was added to each dish. Culture dishes were
kept  at  4  °C  for  30  min  with  gentle  shaking.  After  PBS
washing, cells were scraped and lysed in 100 μl M-PER buffer
with proteinase inhibitors (Thermoscientific). One-hundred
μg  of  total  protein  was  pulled  down  with  NeutrAvidin
(Thermoscientific)  beads  according  to  the  manufacturer’s
protocol. Experiments were performed in biologic replicates.
Luciferase assay: In a 96 well opaque plate (BD Falcon,
Franklin  Lakes,  NJ),  2×104  HEK293T/17  cells  were
transfected with 100 ng TCF reporter plasmid (Cignal Report,
Qiagene) and 0.6 μl Surefect (Qiagene) with or without 100
ng  empty  vector,  pcDNA3.1-LRP5.WT-MycHisC,
pcDNA3.1-LRP5.Q89R-MycHisC,  or  10  ng  pcDNA3.1-
DKK1 vectors. Twenty-four hours after transfection, cells
were  treated  with  or  without  50  or  100  ng/ml  mouse
recombinant  Wnt3a  (R&D  systems,  Minneapolis,  MN)  in
Opti-MEM (Invitrogen) containing 0.5% fetal bovine serum
(Invitrogen),  1%  penicillin+streptomycin,  and  2  mM
glutamine  (Thermoscientific).  Eighteen  hours  later,  Dual-
Glow substrate (Promega) was added to each well, and the
signal was detected with an M200 plate reader (Tecan, NC).
Firefly luciferase activity was normalized to renilla luciferase
activity. Experiments were performed in triplicates (n=3).
Figure 2. Expression of LRP5.WT and
LRP5.Q89R  was  not  different  in
transiently transfected HEK293T cells.
HEK293T  cells  were  transiently
transfected  with  empty,  LRP5.WT-
MycHis  or  LRP5.Q89R-MycHis
expression vector. Whole cell lysate was
analyzed  by  western  immunoblotting
(A). LRP5.WT and LRP5.Q89R fusion
proteins  were  detected  with  an  anti-
cMyc  antibody.  GADPH  served  as  a
loading  control.  (B)  The  expression
levels  of  LRP5.WT  and  LRP5.Q89R
were not statistically different. The optic
density of LRP5 protein bands was first
normalized  to  GAPDH  and  then
normalized to LRP5.WT. Each column
represents the mean±SD of normalized
LRP5  expression  of  five  samples
(LRP5.WT  100%±0  versus
LRP5.Q89R 111%±15%; n=5). NS: not
significant, p>0.05.
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897Statistical analysis: Data were analyzed using the student’s t-
test, with p<0.05 considered statistically significant.
RESULTS
LRP5.Q89R  did  not  change  protein  expression:  LRP5
synthesis and/or degradation could be affected by the Q89R
polymorphism. To answer this question, equal amounts of
vectors  encoding  LRP5.WT-MycHisC  or  LRP5.Q89R-
MycHisC  fusion  protein  were  transfected  into  HEK293T
cells, and their expression levels were compared by western
immunoblotting.  The  expression  of  LRP5  proteins  were
quantitated  by  densitometry.  We  did  not  find  significant
differences  in  the  expression  levels  of  LRP5.WT  and
LRP5.Q89R (Figure 2; t-test, n=5, p>0.05).
LRP5.Q89R  did  not  affect  binding  to  MESD  or  protein
trafficking:  MESD  is  a  molecular  chaperone  involved  in
transporting  LRP5  protein  to  the  cell  surface  [25,27].
Mutations in the first β-propeller domain of LRP5 such as
LRP5.G171V may alter its binding to MESD and lead to
decreased  amount  of  LRP5  on  the  cell  surface  [28].  We
therefore  studied  whether  LRP5.Q89R  affects  MESD
binding.  LRP5.WT-MycHis  or  LRP5.Q89R-MycHis  were
expressed together with MESD-FLAG in HEK293T cells as
well as LRP5.G171V-MycHis as a technical control. LRP5
proteins  were  co-immunoprecipitated  with  an  anti-FLAG
antibody. LRP5.Q89R was not different from LRP5.WT in
binding to MESD, but as expected, the binding of G171V was
compromised (Figure 3A).
Although LRP5.Q89R does not alter MESD binding, it is
still possible that there is less LRP5.Q89R expressed on the
cell  surface.  Therefore,  we  overexpressed  LRP5.WT-
MycHis, LRP5.Q89R-MycHis or LRP5.G171V-MycHisC in
HEK293T  cells,  labeled  surface  proteins  with  biotin  and
pulled them down with Neutravidin beads. We found equal
amounts of LRP5.WT and LRP5.Q89R on the cell surface but
less LRP5.G171V (Figure 3B).
LRP5.Q89R  did  not  affect  the  canonical  Wnt  signaling
pathway: We have shown that Q89R polymorphism did not
change protein expression, molecular chaperone interaction
or protein trafficking. To determine whether LRP5.Q89R is
able to alter the canonical Wnt signaling, we overexpressed
LRP5.WT  or  LRP5.Q89R  in  HEK293T  cells,  and  the
resulting canonical Wnt signaling activity was studied using
a  TCF  luciferase  assay.  Overexpression  of  LRP5.WT  or
LRP5.Q89R  enhanced  basal  and  Wnt3a  induced  Wnt
signaling activity, compared to the empty vector control (t-
test, n=3, p<0.01; Figure 4A). However, the enhancement of
Figure 3. LRP5.Q89R did not affect binding to MESD or protein trafficking in HEK293T cells. LRP5.WT-MycHis, LRP5.Q89R-MycHis or
LRP5.G171V was transiently expressed in HEK293T cells with (A) or without (B) MESD-FLAG by transfection. A: Co-IP of LRP5 and
MESD protein complex. Input: LRP5.WT, LRP5.Q89R, LRP5G171V and MESD protein levels were studied by western immunoblotting
with anti-cMyc or anti-FLAG antibodies, respectively. Whole cell lysate was immunoprecipitated with an anti-FLAG antibody (IP: anti-
FLAG). The enriched protein was analyzed with SDS–PAGE and detected with anti-cMyc antibodies. B: Pull-down of cell surface LRP5
proteins. Proteins on the cell surface were labeled with biotin and pulled down with Neutravidin beads. Protein samples from input and after
pull-down were subjected to western immunoblotting. LRP5.WT, LRP5.Q89R, and LRP5.G171V were probed with an anti-cMyc antibody.
Experiments were performed in biologic replicates and representative data were shown.
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overexpression was similar (t-test, n=3, p>0.05; Figure 4A).
LRP5.Q89R did not change its efficacy to DKK1-mediated
inhibition: It has been reported that mutations in the first β-
propeller domain of LRP5 may alter its sensitivity to DKK1-
mediated  inhibition  [22].  To  test  whether  this  is  true  for
LRP5.Q89R,  we  overexpressed  LRP5  proteins  with  or
without DKK1 in HEK293T cells and the canonical Wnt
signaling activity was measured using the TCF luciferase
assay (Figure 4B). Overexpression of DKK1 had little effect
on basal Wnt signaling activity with or without increased
expression of LRP5.WT or LRP5.Q89R (t-test, n=3, p>0.05).
Wnt3a induced Wnt signaling activity in control, LRP5.WT
and LRP5.Q89R cells was inhibited by DKK1 (t-test, n=3,
p<0.05). However, the remaining Wnt signaling activity in
LRP5.Q89R cells was similar to that of LRP5.WT cells (t-test,
Figure 4. The canonical Wnt signaling activity in HEK293T cells after LRP5 overexpression. HEK293T cells were transiently transfected
with TCF luciferase plasmids and empty, LRP5.WT, or LRP5.Q89R expression vectors. A: Wnt signaling activity after treatment with or
without 50 ng/ml recombinant Wnt3a. B: DKK1 inhibition of Wnt signaling. HEK293T cells were also co-transfected with or without 10 ng
DKK1 expression vector. Cells were treated with or without 100 ng/ml recombinant Wnt3a. Each column represents the mean±SD of relative
luminescence unit (RLU; ×1000) of three samples (n=3). *: p<0.05 **: p<0.01. NS: not significant, p>0.05.
Figure 5. Expression of LRP5.WT and
LRP5.Q89R  was  not  different  in
transiently  transfected  GTM3  cells.
GTM3 cells were transiently transfected
with  empty,  LRP5.WT-MycHis  or
LRP5.Q89R-MycHis  expression
vector. Whole cell lysate was analyzed
by  western  immunoblotting  (A).
LRP5.WT  and  LRP5.Q89R  fusion
proteins  were  detected  with  an  anti-
cMyc  antibody.  GADPH  served  as  a
loading  control.  B:  The  expression
levels  of  LRP5.WT  and  LRP5.Q89R
were not statistically different. The optic
density of LRP5 protein bands was first
normalized  to  GAPDH  and  then
normalized to LRP5.WT. Each column
represents the mean±SD of normalized
LRP5  expression  of  eight  samples
(LRP5.WT  100%±0  versus
LRP5.Q89R 109%±18%; n=8). NS: not
significant, p>0.05.
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899n=3,  p>0.05),  which  suggests  that  DKK1  is  equally
efficacious in interacting with both proteins.
LRP5.Q89R  did  not  affect  protein  expression,  binding  to
MESD or protein trafficking in GTM3 cells: The function of
receptor proteins and cell signaling pathways depends on cell/
tissue type. To test whether LRP5.Q89R behaves differently
in  the  eye,  we  studied  this  polymorphism  in  a  trabecular
meshwork cell line GTM3. Similar to what we observed in
HEK293T cells, LRP5.Q89R did not affect protein expression
(Figure 5; t-test, n=8, p>0.05), binding to MESD (Figure 6A),
or protein trafficking (Figure 6B) in GTM3 cells.
DISCUSSION
LRP5 is a key component of the canonical Wnt signaling
pathway.  Besides  FEVR,  LRP5  polymorphisms  also  are
associated  with  bone  diseases  [8].  Many  bone  disease-
associated  LRP5  polymorphisms  have  been  extensively
studied and can cause two opposite phenotypes: high bone
mass  (HBM)  and  osteoporosis.  LRP5  polymorphisms
associated with HBM are mostly missense mutations found in
the  first  β-propeller  domain,  while  those  associated  with
osteoporosis often cause frame shift or nonsense mutations
[12].
How a single amino acid substitution in LRP5 affects Wnt
signaling  activity  is  still  not  fully  understood.  Zhang  and
colleagues [28] showed that the HBM-associated mutation
LRP5.G171V disrupts LRP5 interaction with MESD, leading
to decreased levels of surface LRP5. The authors proposed
that  this  polymorphism  enhanced  Wnt  signaling  activity
because decreased surface LRP5 reduces the target available
for  DKK1-mediated  inhibition  without  compromising
autocrine  Wnt  activity  in  osteocytes.  However,  Ai  and
colleagues  [29]  suggested  that  although  LRP5  HBM
mutations affect LRP5 expression on the cell surface, they are
able to transduce Wnt signaling similar to LRP5.WT. They
found HBM mutations bind less DKK1 and are therefore less
inhibited.  Other  studies  also  suggested  that  the  first  β-
propeller domain of LRP5 is critical for DKK1-mediated Wnt
inhibition [22]. In addition to these two potential mechanisms,
Semenov  and  He  showed  that  LRP5.G171V  has  reduced
binding to and inhibition by sclerostin (SOST), another Wnt
inhibitor [26]. Interestingly, although DKK1 and SOST are
both LRP5 inhibitors, they work independently and compete
with each other [30].
In  contrast  to  bone  disease-associated  LRP5
polymorphisms,  eye  disease-associated  LRP5
Figure 6. LRP5.Q89R did not affect binding to MESD or protein trafficking in GTM3 cells. LRP5.WT-MycHis, LRP5.Q89R-MycHis or
LRP5.G171V was transiently expressed in GTM3 cells with (A) or without (B) MESD-FLAG by transfection. A: Co-IP of LRP5 and MESD
protein complex. Input: LRP5.WT, LRP5.Q89R, LRP5G171V and MESD protein levels were studied by western immunoblotting with anti-
cMyc or anti-FLAG antibodies, respectively. Whole cell lysate was immunoprecipitated with an anti-FLAG antibody (IP: anti-FLAG). The
enriched protein was analyzed with SDS–PAGE and detected with anti-cMyc antibodies. B: Pull-down of cell surface LRP5 proteins. Proteins
on the cell surface were labeled with biotin and pulled down with Neutravidin beads. Protein samples from input and after pull-down were
subjected to Western immunoblotting. LRP5.WT, LRP5.Q89R and LRP5.G171V were probed with an anti-cMyc antibody. Experiments were
performed in biologic replicates and representative data were shown.
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900polymorphisms have not been extensively studied. The LRP5
polymorphism LRP5.Q89R is particularly interesting to us
because it has been associated with FEVR [19,20] as well as
bone mass density [31], spinal osteoarthritis [32], and Type
III hyperlipoproteinemia [33]. Structural analysis showed that
LRP5.Q89R is located in the first β-propeller domain, where
most  of  the  HBM-associated  polymorphisms  reside.  As
discussed above, it seems that LRP5.Q89R may enhance Wnt
signaling  activity  based  on  its  location.  Nevertheless,
LRP5.Q89R-associated  diseases  all  indicate  that  this
polymorphism appears to impair the canonical Wnt signaling
pathway. However, to our surprise in this study, we did not
find any significant impact of the Q89R polymorphism on
Wnt signaling activity in HEK293T or GTM3 cells. Another
study  of  LRP5.Q89R  in  STF  cells  also  reported  that  this
polymorphism was able to respond to Norrin, a secreted Wnt
pathway activator, provided that FZD4 was also expressed
[20]. However, the effect of the Wnt signaling pathway is
often  cell/tissue-type  dependent,  so  it  is  possible  that
LRP5.Q89R polymorphism may have altered functionality in
other  cell  types.  Furthermore,  we  cannot  rule  out  the
possibility that LRP5.Q89R may respond differently to other
Wnt pathway activators/inhibitors, which may result in altered
signal transduction. Finally, although LRP5.Q89R has been
suggested to be “disease-associated” by genetic screening, it
is  still  possible  that  this  polymorphism  has  no  functional
consequence.  Therefore,  further  studies  of  LRP5
polymorphisms are needed to elucidate their roles in various
associated diseases.
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